Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The MHRA said it had secured £3.6 million over three years to expand its AI Airlock programme, a regulatory sandbox-style route for artificial intelligence as a medical device.
The funding signals that UK regulators see AI in health as a long-term capability problem, not a one-off guidance update. AI tools may change after deployment, use complex data inputs and create evidence questions that traditional device pathways were not built to handle.
For developers, the Airlock can reduce uncertainty by letting products be tested with regulatory oversight. For patients, the crucial issue is whether such sandboxes produce stricter evidence, not simply faster market entry.
Why It Matters
If health AI regulation becomes a competitive advantage, countries will compete on credible speed: fast enough for innovation, serious enough for clinical trust.
What to Watch
Watch which products enter future Airlock phases and whether learnings become binding guidance for AI medical devices.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
MHRAAI AirlockMedical DevicesUK Life Sciences